Following a speech that seemed more campaign rhetoric than policy, President Donald Trump signed an executive order Thursday that's his answer to the Democrats' proposed Medicare for All Act. Read More
Tenaya Therapeutics Inc. CEO Faraz Ali told BioWorld that the company, which raised $92 million in a series B round, has programs from three cardiac platforms "stacked on top of each other" and wants to enter the clinic by the end of 2021 "with at least one of the multiple projects we're advancing." The South San Francisco-based firm wanted not to "let resources be the barrier" as to which goes first, he said. "We wanted the science to dictate that." Read More
DUBLIN – After four years in stealth mode, Arcellx Inc. finally emerged onto open ground, with an $85.7 million series B round under its belt and plans to take its two lead "intelligent" cell therapy programs into clinical development in multiple myeloma and acute myeloid leukemia. Read More
Adicet Bio Inc.'s relatively newly minted president and CEO, Anil Singhal, found the company heading in the right direction when he took over in May, and the company's good standing, including a new $80 million series B fundraiser, is a result of that earlier stewardship. Read More
PERTH, Australia – Australian cell therapy developer Mesoblast Ltd. has completed a AU$75 million (US$50.32 million) capital raising via an oversubscribed placement to existing and new Australian and global institutional investors. Read More
Eli Lilly and Co., of Indianapolis, requested the delisting of its shares from Euronext Paris due to the very low trading volume, costs and administrative requirements related to its secondary listing on Euronext Paris. The board of the exchange has approved the request. Lilly's shares will remain listed on the New York Stock Exchange. Read More
Aprea Therapeutics Inc., of Boston, said it priced its IPO of approximately 5.7 common shares at $15 apiece, the midpoint of its proposed range, for expected gross proceeds of approximately $85 million. The company granted underwriters a 30-day option to purchase up to 850,000 additional shares, potentially adding about $12.8 million to the raise. Read More
WASHINGTON – In case any question remained about who shoulders the blame for the serious lack of viable innovation in the infectious disease specialty, a panel at the Infectious Disease Society of America's IDWeek 2019 came with a surprisingly accusatory subtitle: "How ID Killed Antibiotic Development." Observing what Vivo Capital Managing Partner Chen Yu called "an existential crisis for the specialty," the session served as a call for action for infectious disease (ID) doctors to take control of prescribing, put patient care ahead of cost management, and advocate for both faster changes to clinical guidelines and legislative improvements to better position the industry. Read More
